Published in AIDS Weekly, April 8th, 1996
AR177, an oligonucleotide with demonstrated ability to inhibit HIV integrase, underwent a single-dose Phase I trial at San Francisco General Hospital, California, in HIV positive patients. To date, AR177 has been well tolerated with no drug-related adverse effects.
In preclinical studies, AR177 demonstrated activity against a variety of clinical isolates of HIV, including strains resistant to AZT. In the March 1996 issue of the Journal of Biological Chemistry, Nilabh...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.